ExpreS2ion Biotechnologies

About Us

ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.

Contacts

Bent U. Frandsen

CEO

+45 2222 1019
http://www.expres2ionbio.com
buf@expres2ionbio.com

Keith Alexander

CFO

+45 2222 1019
http://www.expres2ionbio.com
ka@expres2ionbio.com

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Notice of Annual General Meeting in ExpreS2ion Biotech Holding AB

Mon, Apr 26, 2021 08:30 CET

The shareholders of ExpreS2ion Biotech Holding AB, reg. no. 559033-3729, (the "Company"), are hereby convened to the annual general meeting to be held on Wednesday 26 May 2021.This is an unofficial translation of a notice to the Annual General Meeting in ExpreS[2]ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. Information with respect to the coronavirus The Company is mindful of the health and well-being of its shareholders and employees. It´s important for the

Report from ExpreS2ion Biotech Holding AB’s (publ) annual general meeting

Thu, May 23, 2019 21:43 CET

This is an unofficial translation of a report from the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. Today, on May 23, 2019, the annual general meeting of ExpreS2ion Biotech Holding AB (publ) was held. A summary of the decisions that were made follows below. All decisions were taken with required majority.Distribution of results The AGM resolved to dispose of the Company's results according to the Board's proposal in the annual

Correction: Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

Tue, Apr 23, 2019 13:17 CET

This is an unofficial translation of a notice to the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), 559033-3729, are hereby invited to attend the Annual General Meeting on Thursday, May 23, 2019 at 16.00 at Mazars SET's office, Terminalgatan 1, in Helsingborg.Right to participate and registration Shareholders who wish to attend the Annual General Meeting shall · be

Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

Tue, Apr 23, 2019 08:36 CET

There are no items matching the current filter

There are no more items matching the current filter